

A woman in a white blazer and shorts is walking on a boardwalk. She is wearing silver high-heeled sandals. The background is blurred, showing other people and a railing.

Asc for  
**ASCLERA®**  
(Polidocanol) Injection

# ASCLERA®

## (Polidocanol) Injection

### Simple procedure for sustained results

Uncomplicated spider vein treatment ( $\leq 1$  mm)  
patient treated with 0.5% ASCLERA



Before



After

Uncomplicated reticular vein treatment (1-3 mm)  
patient treated with 1% ASCLERA



Before



After

Improvement 18 weeks after last treatment



Visit [www.ASCLERA.com](http://www.ASCLERA.com) for more information THEN ask your Healthcare Provider about ASCLERA to begin your sclerotherapy treatment today.

***methapharm***  
Specialty Pharmaceuticals

Distributed by Methapharm, Inc. Copyright © 2025  
Methapharm, Inc. All rights reserved. ASCLERA® is a registered  
trademark of Chemische Fabrik Kreussler & Co. GmbH

ASCLERA is contraindicated for patients with known allergy to polidocanol and patients with acute thromboembolic diseases. In clinical studies, the following adverse reactions were observed after using ASCLERA and were more common with ASCLERA than placebo: injection site hematoma, injection site irritation, injection site discoloration, injection site pain, injection site itching, injection site warmth, neovascularization, injection site clotting. Please consult the package insert for full prescribing information including warnings and precautions, available on request by calling Methapharm Medical Information at 1-866-701-4636, or to view and download at [www.ASCLERA.com](http://www.ASCLERA.com). To report SUSPECTED ADVERSE REACTIONS, contact Methapharm Medical Information at 1-866-701-4636 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch). For all other ASCLERA inquiries please call 1-833-766-8346. References: 1) ASCLERA® Full Prescribing Information. Methapharm, Inc. 2) Rabe E, Schliephake D, Otto J, Breu FX, et al. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). *Phlebology* 2010;25:124-31.